ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Acne mRNA (messenger ribonucleic acid) vaccine

Its studies are mostly in Acne Vulgaris, led by Sanofi.

Furthest: phase 2, since Aug 4, 20261 company-led study, 1 open or runningNext primary completion: Jul 19, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi11 open or runningphase 2since Aug 4, 2026Aug 4, 2026Jul 19, 2028phase 2 · NCT07756957

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 4, 2026First study: phase 2 study in Acne VulgarisFirst studyNCT07756957 · 410 planned · Canada

Ahead

  1. Jul 19, 2028Primary completion: phase 2 study in Acne VulgarisNCT07756957

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Acne mRNA (messenger ribonucleic acid) vaccine”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07756957Acne Vulgaris · Canada2RecruitingJul 19, 2028410

How it is read

Names in the registry

  • “Acne mRNA (messenger ribonucleic acid) vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.